The present invention relates to compounds having the general formula (I) as described herein; methods of preparing said compounds; and their use in treating Type 1 and/or Type 2 Diabetes Mellitus. The compounds were assayed for binding to serum retinol binding protein (sRBP) and for disruption of the sRBP:transthyretin (TTR) and sRBP:sRBP receptor interaction. The compounds were also assayed for their ability to induce glucose uptake into mouse muscle cells. Also described is a pharmaceutical composition comprising a compound according to the first aspect of the present invention, and use thereof in treating Type 1 and Type 2 Diabetes.
本发明涉及具有如下所述的一般式(I)的化合物;制备该化合物的方法;以及它们在治疗1型和/或2型糖尿病中的应用。对这些化合物进行了与血清
视黄醇结合蛋白(sRBP)的结合和对sRBP:
甲状腺素转运蛋白(
TTR)和sRBP:sRBP受体相互作用的破坏的测定。这些化合物还被检测其促进小鼠肌肉细胞中
葡萄糖摄取的能力。还描述了包含根据本发明第一方面的化合物的药物组合物,以及其在治疗1型和2型糖尿病中的用途。